
Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing… Read More

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More

Thanks to their low toxicity and high specificity, therapeutic antibodies have enjoyed incredible market success across a range of disease categories. The global antibody discovery market, valued at $11.15 billion in 2025, is expected to surge to $35.35 billion by 2035. Experts predict this growth will… Read More

Download this exclusive eBook from Fluidic Sciences to learn more about: How the global antibody discovery market could evolve in the next 10 years How new technologies are improving efficiency and downstream success rates in antibody discovery Multiplexed rapid B cell screening and the future of antibody discovery… Read More

Dr Yi Ye and Dr Vanessa Uzonwan examine research that suggests how cancer drugs may be repurposed to manage oral cancer pain. Cancer-associated pain remains a major clinical challenge, particularly in oral squamous cell carcinoma (OSCC), where patients experience severe pain during eating and speaking alongside substantial declines in quality of life. Despite advances in… Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More


Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry. Download this exclusive eBook to learn more about: Autotaxin… Read More

This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry.


Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

The University of Dundee has revealed plans to develop therapies to tackle a deadly tropical disease. The £10 million ($13.4 million) project will accelerate research on new therapies for schistosomiasis. The disease is a chronic illness caused by microscopic worms found in contaminated freshwater. Found largely in Africa, South America, and Asia,… Read More